However, studies assessing breast cancer progression that were using CB2 agonist administered within 7°days of tumor transplant have shown small tumor volumes under 100 mm3 using peritumoral (Elbaz et al., 2017) or systemic (Hanlon et al., 2016) administration. The gene discussed is CNR2; the disease is breast carcinoma.